Steroid Compound Selective GABAA Modulation for Hepatic Encephalopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatic encephalopathy are inadequate as they often induce side effects such as convulsions due to inhibition of GABA binding at GABAA receptors and do not effectively address cognitive and motor impairments associated with liver disease-induced hyperammonemia.
Innovation Solution
The compound 3α-ethynyl-3β-hydroxyandrostan-17-one oxime acts as a selective inhibitor of endogenous steroids that induce sedation and cognitive impairment, without affecting ammonia levels, thereby providing a safer and more effective treatment for hepatic encephalopathy by modulating GABAA receptors without inhibiting GABA binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GABA binding at GABAA receptors is inhibited to treat hepatic encephalopathy, then sedation and cognitive impairment are reduced, but convulsions occur as a harmful side effect
Solution Approach 1:
The invention segments the action at the GABAA receptor into two distinct pathways: one for endogenous steroids (blocked by the compound) and one for GABA (preserved). This selective inhibition of steroid modulation while maintaining GABA binding resolves the contradiction by eliminating convulsions while retaining treatment effectiveness.
Solution Approach 2:
The compound 3α-ethynyl-3β-hydroxyandrostan-17-one oxime acts as an intermediary that specifically interferes with the steroid-GABAA receptor interaction without blocking GABA binding. This selective intermediary action allows the patent to achieve therapeutic benefits while avoiding harmful side effects.
2Reliability
If endogenous steroids are not inhibited, then GABAA receptor modulation continues, but sedation and cognitive impairment persist in hepatic encephalopathy patients
Solution Approach 1:
The compound segments the modulation pathways by specifically blocking endogenous steroid action while preserving GABAergic transmission. This selective segmentation eliminates sedation and cognitive impairment caused by steroids without compromising overall GABAA receptor function.
Solution Approach 2:
The invention changes the parameter of receptor modulation selectivity by designing a compound that specifically targets steroid-modulated GABAA receptors. This parameter change allows differentiation between pathological steroid effects and physiological GABA effects, resolving the contradiction between treatment effectiveness and cognitive preservation.
3Reliability
If conventional treatments are used for hepatic encephalopathy, then ammonia levels are reduced, but side effects such as convulsions occur
Solution Approach 1:
The compound serves as a selective intermediary that blocks only the pathological steroid-GABAA receptor pathway while leaving the beneficial GABA pathway intact. This intermediary action provides a new mechanism for treating hepatic encephalopathy that avoids the convulsive side effects of conventional GABA-antagonist approaches.
Solution Approach 2:
The invention changes the therapeutic parameter from non-selective GABA receptor antagonism to selective steroid-modulated receptor antagonism. This parameter change enables ammonia reduction and symptom management without triggering convulsions, resolving the contradiction between treatment effectiveness and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
3α-ethynyl-3β-hydroxyandrostan-17-one oxime restores motor and cognitive functions in animal models of hepatic encephalopathy without affecting ammonia levels, offering a promising therapeutic option for hepatic encephalopathy and related disorders.
Implementation Method 1
3α-ethynyl-3β-hydroxyandrostan-17-one oxime is able to selectively inhibit the positive modulation of the GABAA receptor by endogenous steroids such as allopregnanolone and tetrahydrodeoxycorticosterone (THDOC)
Data Source
AI summary
The present invention provides the steroidal compound 3α-ethynyl-3β-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.